MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
Healthcare
$6.65 +3.11%
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
52W Low $9.10High $40.43
Volume 0.42M
Average 0.73M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$138.14M
FY 2025 · Annual
Investing Cash Flow
-$323.21M
FY 2025 · Annual
Financing Cash Flow
$469.82M
FY 2025 · Annual
+298.0% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 35.27M |
| Operating Cash Flow | (26.58M) | (52.01M) | (78.82M) | (138.14M) |
| Capital Expenditures | (746K) | (462K) | (770K) | (473K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (125.02M) | (408.23M) |
| Sales of Investments | 0 | 0 | 45M | 85.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (746K) | (462K) | (80.79M) | (323.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.17M | 104.57M | 120.25M | 474.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.18M | 104.57M | (2.19M) | (5.02M) |
| Financing Cash Flow | 33.17M | 104.57M | 118.06M | 469.82M |
| Effect of Forex Changes | 21.81M | 0 | 27K | 0 |
| Net Change in Cash | 27.67M | 52.1M | (41.52M) | 8.48M |
| Free Cash Flow | (27.32M) | (52.47M) | (79.59M) | (138.61M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$161.2M
+ D&A$578.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$12.8M
+ Other Non-Cash$35.3M
= Operating Cash Flow-$138.1M
- Capex-$473.0K
= Free Cash Flow-$138.6M
Analysis
FY2025 free cash flow is -$138.6M. FCF conversion is 86.0% of net income. Operating cash flow was -$138.1M, with capex of -$473.0K. The largest bridge item is Other Non-Cash at $35.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 |
Does MPLT generate free cash flow?
MapLight Therapeutics, Inc. (MPLT) generated -$138.61M of free cash flow in fiscal 2025.
How much operating cash flow does MPLT produce?
Operating cash flow was -$138.14M, before capital expenditures of $473,000.00.
Continue the stock analysis
Jump to another research area for this company.